WARNINGS HEMABATE Sterile Solution (carboprost tromethamine), like other potent oxytocic agents, should be used only with strict adherence to recommended dosages. HEMABATE should be used by medically trained personnel in a hospital which can provide immediate intensive care and acute surgical facilities.
Use: Labeled indications
- INDICATIONS AND USAGE HEMABATE Sterile Solution is indicated for aborting pregnancy between the 13th and 20th weeks of gestation as calculated from the first day of the last normal menstrual period and in the following…
Full indications and usage US FDA label
INDICATIONS AND USAGE HEMABATE Sterile Solution is indicated for aborting pregnancy between the 13th and 20th weeks of gestation as calculated from the first day of the last normal menstrual period and in the following conditions related to second trimester abortion: 1. Failure of expulsion of the fetus during the course of treatment by another method; 2.
Premature rupture of membranes in intrauterine methods with loss of drug and insufficient or absent uterine activity; 3. Requirement of a repeat intrauterine instillation of drug for expulsion of the fetus; 4. Inadvertent or spontaneous rupture of membranes in the presence of a previable fetus and absence of adequate activity for expulsion.
HEMABATE is indicated for the treatment of postpartum hemorrhage due to uterine atony which has not responded to conventional methods of management. Prior treatment should include the use of intravenously administered oxytocin, manipulative techniques such as uterine massage and, unless contraindicated, intramuscular ergot preparations.
Studies have shown that in such cases, the use of HEMABATE has resulted in satisfactory control of hemorrhage, although it is unclear whether or not ongoing or delayed effects of previously administered ecbolic agents have contributed to the outcome. In a high proportion of cases, HEMABATE used in this manner has resulted in the cessation of life threatening bleeding and the avoidance of emergency surgical intervention.
Contraindications
CONTRAINDICATIONS 1. Hypersensitivity (including anaphylaxis and angioedema) to HEMABATE Sterile Solution [see ADVERSE REACTIONS, Post-marketing Experience] 2. Acute pelvic inflammatory disease 3. Patients with active cardiac, pulmonary, renal or hepatic disease
US FDA labelDosing: Adult
Dosage and administration (US label) US FDA label
DOSAGE AND ADMINISTRATION 1. Abortion and Indications 1–4 An initial dose of 1 mL of HEMABATE Sterile Solution (containing the equivalent of 250 micrograms of carboprost) is to be administered deep in the muscle with a tuberculin syringe. Subsequent doses of 250 micrograms should be administered at 1½ to 3½ hour intervals depending on uterine response.
An optional test dose of 100 micrograms (0.4 mL) may be administered initially. The dose may be increased to 500 micrograms (2 mL) if uterine contractility is judged to be inadequate after several doses of 250 micrograms (1 mL). The total dose administered of carboprost tromethamine should not exceed 12 milligrams and continuous administration of the drug for more than two days is not recommended. 2.
For Refractory Postpartum Uterine Bleeding An initial dose of 250 micrograms of HEMABATE Sterile Solution (1 mL of HEMABATE) is to be given deep, intramuscularly. In clinical trials it was found that the majority of successful cases (73%) responded to single injections. In some selected cases, however, multiple dosing at intervals of 15 to 90 minutes was carried out with successful outcome.
The need for additional injections and the interval at which these should be given can be determined only by the attending physicians as dictated by the course of clinical events. The total dose of HEMABATE should not exceed 2 milligrams (8 doses). Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit.
Dosing: Altered kidney function
No kidney-specific text is available from the US label for this generic yet. Check the Philippine package insert in the products table.
Kidney-specific guidance from renalcarematters.com: in preparation.
Dosing: Pediatric
Pediatric use (US label) US FDA label
Pediatric Use Safety and effectiveness in pediatric patients have not been established.
Dosage forms
Philippines
- Solution for injection: 125 mcg/0.5 mL, 125 mcg/0.5 mL and 250 mcg/mL, 250 mcg/mL
- ): 250 mcg/mL (125 mcg/0.5 mL
- ) solution for intramuscular injection: 250 mcg/mL (as 125 mcg/0.5 mL and as 250 mcg/mL
- Solution for intramuscular injection: 250 mcg/mL
Registered products in the Philippines
7 products registered with the Food and Drug Administration (FDA) Philippines list Carboprost as the generic name. Registration status changes; confirm a product's current status on the FDA portal before relying on it.
All registered products7
| Package insert | |||||||
|---|---|---|---|---|---|---|---|
Carbsaph-AltCarboprost (as tromethamine) | 250 mcg/mL Solution for Intramuscular Injection0.5 mL and 1 mL USP Type I clear glass ampoule in PVC tray (Box of 5’s and 10’s) | Rx | Althea Pharma Pvt. Ltd.India | Nelpa Lifesciences, Inc.Trader: N/A | DRP-18742 | Sep 3, 2031 | |
EndoprostCarboprost (as tromethamine) | 125 mcg/0.5 mL Solution for Injection (I.M.)0.5 mL net volume in 2 mL capacity USP Type I clear and colorless glass vial enclosed with rubber bung and aluminum seal with ice green flip-off cap in a tray (Box of 1's and 5's) | Rx | Bharat Serums and Vaccines LimitedIndia | BSV Bioscience Phils. Inc. | DR-XY44686 | Jun 30, 2031 | |
EndoprostCarboprost (as tromethamine) | 250 mcg/mL Solution for Injection (I.M.)1 mL net volume in 2 mL capacity USP Type I clear and colorless glass vial enclosed with rubber bung and aluminum seal with orange flip-off cap in a tray (Box of 5's) | Rx | Bharat Serums and Vaccines LimitedIndia | BSV Bioscience Phils. Inc. | DR-XY44687 | Mar 2, 2031 | |
EvacarbCarboprost (as trometamol) | 125 mcg/0.5 mL and 250 mcg/mL Solution for Injection (for I.M. Use only)USP Type I Clear Glass Ampoule in 0.5 mL and 1 mL (net content) Box of 5 and 10 ampoules in plastic tray. | Rx | Celon Laboratories Private LimitedIndia | Medethix Inc. | DRP-12325 | Mar 7, 2031 | |
EvaprostCarboprost (as trometamol) | 250 mcg/mL (as 125 mcg/0.5 mL and as 250 mcg/mL) Solution for Intramuscular Injection0.5 mL (net content) in 1 mL-capacity USP Type I Clear and Colorless Glass Ampoule (Box of 10 Ampoules in a Plastic Tray); 1 mL (net content) in 1 mL-capacity USP Type I Clear and Colorless Glass Ampoule (Box of 10 Ampoules in a Plastic Tray) | Rx | CELON LABORATORIES PRIVATE LIMITEDIndia | MULTICARE PHARMACEUTICALS PHILS. INC.Importer: I.E. Medica, Inc. | DRP-10595 | Mar 13, 2029 | |
NoneCarboprost (as tromethamine) | Solution for Injection (IM) 250 mcg/ml (125 mcg/0.5 ml)USP Type I clear glass ampoule x 1mL (0.5 mL net content) Box of 10's; USP Type I clear glass ampoule x 1mL (1 mL net content) Box of 10's; USP Type I clear glass ampoule x 1mL (0.5 mL net content) Box of 5's; USP Type I clear glass ampoule x 1mL (1 mL net content) Box of 5's | Rx | Belco PharmaIndia | Nelpa Lifesciences, Inc.Importer: Ollen Pharma Trading Inc. | DRP-18013-01 | Dec 5, 2030 | |
UtrofixCarboprost (as Tromethamine) | 250 mcg/mL Solution for Injection (I.M.)USP Type III glass vial x 2 mL (net content) with bromobutyl rubber stopper and aluminum seal and blue flip-off cap (Box of 10’s) | Rx | Ciron Drug & Pharmaceutical Pvt. Ltd.India | Biocare Lifesciences, Inc. | DRP-18496 | Aug 3, 2031 |
Source: FDA Philippines product registration database. "Valid until" is the registration validity date listed by the FDA; a past date may mean a renewal is pending. Package insert links point to files published by the FDA.
Warnings/Precautions
The boxed warning is shown at the top of this page.
Warnings and precautions (US label) US FDA label
WARNINGS HEMABATE Sterile Solution (carboprost tromethamine), like other potent oxytocic agents, should be used only with strict adherence to recommended dosages. HEMABATE should be used by medically trained personnel in a hospital which can provide immediate intensive care and acute surgical facilities. HEMABATE does not appear to directly affect the fetoplacental unit.
Therefore, the possibility does exist that the previable fetus aborted by HEMABATE could exhibit transient life signs. HEMABATE is not indicated if the fetus in utero has reached the stage of viability. HEMABATE should not be considered a feticidal agent. Evidence from animal studies has suggested that certain other prostaglandins have some teratogenic potential.
Although these studies do not indicate that HEMABATE is teratogenic, any pregnancy termination with HEMABATE that fails should be completed by some other means. This product contains benzyl alcohol. Benzyl alcohol has been reported to be associated with a fatal "Gasping Syndrome" in premature infants.
Drug interactions
Drug interactions (US label) US FDA label
Drug Interactions HEMABATE may augment the activity of other oxytocic agents. Concomitant use with other oxytocic agents is not recommended.
Adverse reactions
Adverse reactions (US label) US FDA label
ADVERSE REACTIONS The adverse effects of HEMABATE Sterile Solution are generally transient and reversible when therapy ends. The most frequent adverse reactions observed are related to its contractile effect on smooth muscle. In patients studied, approximately two-thirds experienced vomiting and diarrhea, approximately one-third had nausea, one-eighth had a temperature increase greater than 2° F, and one-fourteenth experienced flushing.
The pretreatment or concurrent administration of antiemetic and antidiarrheal drugs decreases considerably the very high incidence of gastrointestinal effects common with all prostaglandins used for abortion. Their use should be considered an integral part of the management of patients undergoing abortion with HEMABATE.
Of those patients experiencing a temperature elevation, approximately one-sixteenth had a clinical diagnosis of endometritis. The remaining temperature elevations returned to normal within several hours after the last injection. Adverse effects observed during the use of HEMABATE for abortion and for hemorrhage, not all of which are clearly drug related, in decreasing order of frequency include: Vomiting Nervousness Diarrhea Nosebleed Nausea Sleep disorders Flushing or hot flashes Dyspnea Chills or shivering Tightness in chest Coughing Wheezing Headaches Posterior cervical perforation Endometritis Weakness Hiccough Diaphoresis Dysmenorrhea-like pain Dizziness Paresthesia Blurred vision Backache Epigastric pain Muscular pain Excessive thirst Breast tenderness Twitching eyelids Eye pain Gagging, retching Drowsiness Dry throat Dystonia Sensation of choking Asthma Thyroid storm Injection site pain Syncope Tinnitus Palpitations Vertigo Rash Vaso-vagal syndrome Upper respiratory infection Dryness of mouth Leg cramps Hyperventilation Perforated uterus Respiratory distress Anxiety Hematemesis Chest pain Taste alterations Retained placental fragment Urinary tract infection Shortness of breath Septic shock Fullness of throat Torticollis Uterine sacculation Lethargy Faintness, light-headedness Hypertension Uterine rupture Tachycardia Pulmonary edema Endometritis from IUCD The most common complications when HEMABATE was utilized for abortion requiring additional treatment after discharge from the hospital were endometritis, retained placental fragments, and excessive uterine bleeding, occurring in about one in every 50 patients.
Post-marketing experience Hypersensitivity reactions (e.g. Anaphylactic reaction, Anaphylactic shock, Anaphylactoid reaction, Angioedema).
Adverse reaction frequency tables (US label) US FDA label
| Vomiting | Nervousness |
| Diarrhea | Nosebleed |
| Nausea | Sleep disorders |
| Flushing or hot flashes | Dyspnea |
| Chills or shivering | Tightness in chest |
| Coughing | Wheezing |
| Headaches | Posterior cervical perforation |
| Endometritis | Weakness |
| Hiccough | Diaphoresis |
| Dysmenorrhea-like pain | Dizziness |
| Paresthesia | Blurred vision |
| Backache | Epigastric pain |
| Muscular pain | Excessive thirst |
| Breast tenderness | Twitching eyelids |
| Eye pain | Gagging, retching |
| Drowsiness | Dry throat |
| Dystonia | Sensation of choking |
| Asthma | Thyroid storm |
| Injection site pain | Syncope |
| Tinnitus | Palpitations |
| Vertigo | Rash |
| Vaso-vagal syndrome | Upper respiratory infection |
| Dryness of mouth | Leg cramps |
| Hyperventilation | Perforated uterus |
| Respiratory distress | Anxiety |
| Hematemesis | Chest pain |
| Taste alterations | Retained placental fragment |
| Urinary tract infection | Shortness of breath |
| Septic shock | Fullness of throat |
| Torticollis | Uterine sacculation |
| Lethargy | Faintness, light-headedness |
| Hypertension | Uterine rupture |
| Tachycardia | |
| Pulmonary edema | |
| Endometritis from IUCD |
Pregnancy considerations
Pregnancy (US label) US FDA label
Pregnancy Teratogenic Effects Animal studies do not indicate that HEMABATE is teratogenic, however, it has been shown to be embryotoxic in rats and rabbits and any dose which produces increased uterine tone could put the embryo or fetus at risk.
Pharmacokinetics
Pharmacokinetics (US label) US FDA label
CLINICAL PHARMACOLOGY Carboprost tromethamine administered intramuscularly stimulates in the gravid uterus myometrial contractions similar to labor contractions at the end of a full term pregnancy. Whether or not these contractions result from a direct effect of carboprost on the myometrium has not been determined. Nonetheless, they evacuate the products of conception from the uterus in most cases.
Postpartum, the resultant myometrial contractions provide hemostasis at the site of placentation. Carboprost tromethamine also stimulates the smooth muscle of the human gastrointestinal tract. This activity may produce the vomiting or diarrhea or both that is common when carboprost tromethamine is used to terminate pregnancy and for use postpartum.
In laboratory animals and also in humans carboprost tromethamine can elevate body temperature. With the clinical doses of carboprost tromethamine used for the termination of pregnancy, and for use postpartum, some patients do experience transient temperature increases. In laboratory animals and in humans large doses of carboprost tromethamine can raise blood pressure, probably by contracting the vascular smooth muscle.
With the doses of carboprost tromethamine used for terminating pregnancy, this effect has not been clinically significant. In laboratory animals and also in humans carboprost tromethamine can elevate body temperature. With the clinical doses of carboprost tromethamine used for the termination of pregnancy, some patients do experience temperature increases.
In some patients, carboprost tromethamine may cause transient bronchoconstriction. Drug plasma concentrations were determined by radioimmunoassay in peripheral blood samples collected by different investigators from 10 patients undergoing abortion. The patients had been injected intramuscularly with 250 micrograms of carboprost at two hour intervals.
Blood levels of drug peaked at an average of 2060 picograms/mL one-half hour after the first injection then declined to an average concentration of 770 picograms/mL two hours after the first injection just before the second injection. The average plasma concentration one-half hour after the second injection was slightly higher (2663 picograms/mL) than that after the first injection and decreased again to an average of 1047 picograms/mL by two hours after the second injection.
Plasma samples were collected from 5 of these 10 patients following additional injections of the prostaglandin. The average peak concentrations of drug were slightly higher following each successive injection of the prostaglandin, but always decreased to levels less than the preceding peak values by two hours after each injection.
Five women who had delivery spontaneously at term were treated immediately postpartum with a single injection of 250 micrograms of carboprost tromethamine. Peripheral blood samples were collected at several times during the four hours following treatment and carboprost tromethamine levels were determined by radioimmunoassay.
The highest concentration of carboprost tromethamine was observed at 15 minutes in two patients (3009 and 2916 picograms/mL), at 30 minutes in two patients (3097 and 2792 picograms/mL), and at 60 minutes in one patient (2718 picograms/mL).
Formulary and pricing (Philippines)
Government price references
| Preparation | Price (PHP) | Unit | Type |
|---|---|---|---|
| Carboprost 125 mcg/0.5 mL Solution | ₱114.00–₱280.00Reference ₱172.50 | per unit | DPRI procurement range |
| Carboprost 250 mcg/mL Solution | ₱202.00–₱480.00Reference ₱233.00 | per unit | DPRI procurement range |
Range = lowest-highest procurement price (highest usable only in GIDA areas); reference_price = 2021 DPRI ceiling (median)
These are government procurement and reimbursement references, not retail prices. Sources:
- DOH Drug Price Reference Index (DPRI) 2021, 9th edition (as of September 17, 2021); https://caro.doh.gov.ph/wp-content/uploads/2021/09/2021DPRI-as-of-9-17-2021.pdf, as of September 17, 2021
Formulary and coverage
| Philippine National Formulary | Listed as Carboprost |
| PNF listing | Inj.: 125 mcg/0.5 mL solution for injection, 0.5 mL ampul/vial |
| PNF listing | Inj.: 250 mcg/mL solution for injection, 1 mL |
| PNF listing | Inj.: ampule/vial |
| PhilHealth GAMOT | No |
Sources:
- PNF Essential Medicines List, 8th ed. (as of November 2, 2022), DOH; https://www.philhealth.gov.ph/partners/providers/pdf/PNF-EML_11022022.pdf, as of November 2, 2022
Check availability
Prices and stock vary by branch; renalcarematters.com does not sell medicines or receive payment from pharmacies.
References
- U.S. Food and Drug Administration. Hemabate · Pharmacia & Upjohn Company LLC [US FDA-approved label, version 14, March 30, 2026]. Via DailyMed/openFDA. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3d282998-ff0c-480a-bd80-155606ef0a65
- Food and Drug Administration Philippines. Verification portal (product registrations). https://verification.fda.gov.ph
- PNF Essential Medicines List, 8th ed. (as of November 2, 2022), DOH; https://www.philhealth.gov.ph/partners/providers/pdf/PNF-EML_11022022.pdf
- DOH Drug Price Reference Index (DPRI) 2021, 9th edition (as of September 17, 2021); https://caro.doh.gov.ph/wp-content/uploads/2021/09/2021DPRI-as-of-9-17-2021.pdf
This page shows official label and registry text only; no renalcarematters.com clinical summary has been approved for it yet.
Last updated: .